Novartis hopes that Vertex Pharmaceuticals' structure-based drug design will deliver at least eight product candidates that target protein kinases into its development pipeline in the next six years. That's the goal for their new alliance, under which Novartis is providing Vertex $200 million in research funding, another $200 million as an interest-free loan (which will be forgiven to the extent that the monies drawn cover development of products Novartis accepts for development), milestones, and royalties. In fact, Vertex could receive as much as $600 million prior to commercialization--more than the industry benchmark for target discovery deals, the $425 million Bayer/Millennium collaboration. But unlike that deal, in which technology exchange was a vital component, this is an outsourcing by Novartis of its R&D in the area--accounting for about a third of its current R&D spending on external collaborations.
Novartis AG hopes that Vertex
Pharmaceuticals Inc. 's structure-based
drug design will deliver at least eight product
candidates—already vetted for market size and validated in
early-stage clinical testing—into its development pipeline in
the next six years. That's the target for their new alliance, under
which Novartis is providing Vertex $200 million in laboratory
research funding over six years and another $200 million in the
form of an interest-free loan to conduct preclinical and clinical
proof-of-concept testing of small-molecule protein kinase
inhibitors Vertex identifies using its high-throughput
chemogenomics platform [See Deal].
In exchange, Novartis gets to select for commercialization up to eight product candidates which meet its criteria—including a market size...
Candid conversations with C-suite leaders.
Keep up with strategy, innovation and evolving trends across life science industries.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.